We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cadence (CDNS) Teams Up With Antiviral Discovery Consortium
Read MoreHide Full Article
Cadence Design Systems, Inc (CDNS - Free Report) is teaming up with the Antiviral Platform (“ASAP”) Discovery Consortium to develop antivirals to prevent pandemics in the future. CDNS will offer its OpenEye molecular design software to drive the artificial intelligence (AI)-driven structure-enabled ASAP platform.
The goal of the AI-driven ASAP Discovery Consortium is to fast-track structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics equitably and affordably across the globe.
The ASAP Discovery Consortium is an Antiviral Drug Discovery U19 Center for Pathogens of Pandemic Concern. It is funded by the National Institute of Allergy and Infectious Diseases, which is a part of the National Institutes of Health, through a $68 million funding as part of the Antiviral Program for Pandemics.
The ASAP Discovery Consortium boasts partners like the Stanford University School of Medicine, Diamond Light Source, the Weizmann Institute of Science, Medchemica, Mount Sinai and the Fred Hutchinson Cancer Center. It also has a worldwide network of scientists and industry collaborators.
OpenEye’s software will help scientists develop therapeutics for less-researched infectious diseases. OpenEye’s various applications, toolkits and Orion platform will assist computational chemists in creating a strong antiviral drug discovery pipeline by leveraging structural biology, AI, machine learning (“ML”) technology and computational chemistry.
Cadence acquired OpenEye Scientific Software for about $500 million in cash in September 2022. With OpenEye’s acquisition, pharmaceutical and biotechnology companies will be able to work on robust drug discovery solutions by combining OpenEye’s molecular modeling and simulation software solutions with Cadence’s algorithmic and solver expertise, data management infrastructure, as well as innovative AI/ML and cloud solutions.
CDNS currently carries a Zacks Rank #3 (Hold). In the past year, the stock has gained 59.7% compared with the Zacks sub-industry’s growth of 46.5%.
The Zacks Consensus Estimate for Blackbaud’s 2023 EPS improved 1.8% in the past 60 days to $3.86. BLKB’s long-term earnings growth rate is 23.4%.
Blackbaud’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 10.6%. Shares of BLKB have surged 49.3% in the past year.
The Zacks Consensus Estimate for BlackBerry’s fiscal 2024 EPS has remained unchanged in the past 30 days at 4 cents. BB’s earnings outpaced the Zacks Consensus Estimate in three of the last four quarters, the average surprise being 55%. Shares of BB have lost 7.4% in the past year.
The Zacks Consensus Estimate for Woodward’s fiscal 2024 EPS has improved 6.9% in the past 60 days to $4.92.
WWD’s earnings outpaced the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.7%. Shares of WWD have jumped 39.2% in the past year.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Cadence (CDNS) Teams Up With Antiviral Discovery Consortium
Cadence Design Systems, Inc (CDNS - Free Report) is teaming up with the Antiviral Platform (“ASAP”) Discovery Consortium to develop antivirals to prevent pandemics in the future. CDNS will offer its OpenEye molecular design software to drive the artificial intelligence (AI)-driven structure-enabled ASAP platform.
The goal of the AI-driven ASAP Discovery Consortium is to fast-track structure-based open-science antiviral drug discovery and deliver oral antivirals for pandemics equitably and affordably across the globe.
The ASAP Discovery Consortium is an Antiviral Drug Discovery U19 Center for Pathogens of Pandemic Concern. It is funded by the National Institute of Allergy and Infectious Diseases, which is a part of the National Institutes of Health, through a $68 million funding as part of the Antiviral Program for Pandemics.
The ASAP Discovery Consortium boasts partners like the Stanford University School of Medicine, Diamond Light Source, the Weizmann Institute of Science, Medchemica, Mount Sinai and the Fred Hutchinson Cancer Center. It also has a worldwide network of scientists and industry collaborators.
Cadence Design Systems, Inc. Price and Consensus
Cadence Design Systems, Inc. price-consensus-chart | Cadence Design Systems, Inc. Quote
OpenEye’s software will help scientists develop therapeutics for less-researched infectious diseases. OpenEye’s various applications, toolkits and Orion platform will assist computational chemists in creating a strong antiviral drug discovery pipeline by leveraging structural biology, AI, machine learning (“ML”) technology and computational chemistry.
Cadence acquired OpenEye Scientific Software for about $500 million in cash in September 2022. With OpenEye’s acquisition, pharmaceutical and biotechnology companies will be able to work on robust drug discovery solutions by combining OpenEye’s molecular modeling and simulation software solutions with Cadence’s algorithmic and solver expertise, data management infrastructure, as well as innovative AI/ML and cloud solutions.
CDNS currently carries a Zacks Rank #3 (Hold). In the past year, the stock has gained 59.7% compared with the Zacks sub-industry’s growth of 46.5%.
Image Source: Zacks Investment Research
Stocks to Consider
Some better-ranked stocks worth consideration in the broader technology space are Blackbaud (BLKB - Free Report) , BlackBerry (BB - Free Report) and Woodward (WWD - Free Report) , each carrying a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Zacks Consensus Estimate for Blackbaud’s 2023 EPS improved 1.8% in the past 60 days to $3.86. BLKB’s long-term earnings growth rate is 23.4%.
Blackbaud’s earnings beat the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 10.6%. Shares of BLKB have surged 49.3% in the past year.
The Zacks Consensus Estimate for BlackBerry’s fiscal 2024 EPS has remained unchanged in the past 30 days at 4 cents. BB’s earnings outpaced the Zacks Consensus Estimate in three of the last four quarters, the average surprise being 55%. Shares of BB have lost 7.4% in the past year.
The Zacks Consensus Estimate for Woodward’s fiscal 2024 EPS has improved 6.9% in the past 60 days to $4.92.
WWD’s earnings outpaced the Zacks Consensus Estimate in each of the last four quarters, the average surprise being 14.7%. Shares of WWD have jumped 39.2% in the past year.